GlassScriptPhysician profile
David A Schwartz
NPI 1629065156
$3,912.46
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,017 · 2020: $295 · 2021: $369 · 2022: $1,748 · 2023: $369 · 2024: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $483.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $800.00 | 2022 | |
| Astellas Pharma US INC | $406.01 | 2019-2023 | Lexiscan |
| Novartis Pharmaceuticals Corporation | $397.62 | 2021-2024 | |
| Amgen INC. | $376.14 | 2019-2023 | Repatha |
| Amarin Pharma, INC. | $330.24 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $209.63 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $200.21 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $152.87 | 2021-2023 | Verquvo |
| Pfizer INC. | $143.30 | 2019-2023 | |
| Boston Scientific Corporation | $115.41 | 2019-2023 | Bodyguardian |
| Novo Nordisk INC | $105.66 | 2021-2023 | Rybelsus, Ozempic |
| Regeneron Healthcare Solutions, INC. | $96.88 | 2019 | |
| Janssen Pharmaceuticals, INC | $77.27 | 2021-2023 | Xarelto |
| Esperion Therapeutics, INC. | $70.28 | 2021-2022 | |
| Philips North America LLC | $55.93 | 2019-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $55.17 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.79 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $47.26 | 2022 | |
| Itamar Medical INC | $31.00 | 2022-2023 | Watchpatone |
| Regeneron Pharmaceuticals, INC. | $26.47 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $21.52 | 2023 | Farxiga |
| Ge Healthcare | $21.39 | 2021 | |
| Gilead Sciences, INC. | $19.88 | 2019 | |
| Abbott Laboratories | $18.66 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.05 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $16.59 | 2023 | Arcalyst |
| Teleflex LLC | $12.89 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.73 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.40 | 2020 | |
| Chiesi USA, INC. | $12.21 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.